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Introduction
Inflammatory bowel disease (IBD) is hypothesized to arise from a loss of immune tolerance toward antigens derived from commensal microbiota. While it is widely accepted that tolerance is maintained by a balance between effector and regulatory T cells in the mucosa [1] , recent genetic findings in Crohn's disease (CD) have demonstrated the importance of intestinal epithelial cells (IECs) [1, 2] . In addition to acting as a physical barrier, IECs, specifically goblet and Paneth cells, secrete mucins and antimicrobial peptides (AMPs) respectively, which form a somewhat impenetrable barrier lining the luminal surface [3, 4] . Unlike mucins, which are well known to maintain intestinal tolerance, the link between AMPs and immune tolerance is not established [4, 5] . The most widely studied class of intestinal AMPs is alpha (α) defensins, which are small (3) (4) (5) kDa) cationic proteins with broad spectrum activity against gram positive and negative bacteria, fungi, viruses and parasites [6] . Alpha-defensins, specifically human defensin 5 (HD-5) and human defensin 6 (HD-6), are first produced and stored as pro-proteins.
Upon secretion, often induced by commensal organisms [7] , HD-5 and HD-6 are cleaved by Paneth cell trypsin into their mature active form [8, 9] . Elimination of Paneth cells in mice results in an accumulation of bacteria within the lamina propria (LP) and mesenteric lymph node (MLN), thus confirming the importance of AMPs in the intestine [10] .
Alterations in AMP expression within the intestine lead to overgrowth of commensal bacteria and colonization by more pathogenic organisms [11] . These studies allude to a function of intestinal AMPs for maintaining a sterile environment proximal to the apical surface of IECs, limiting the density of commensal bacteria and preventing access of commensal antigens to the underlying resident immune cells.
Alpha-defensins are distinguished from their counterpart, beta-defensins, by a distinct disulfide linkage between six conserved cysteines [6] . Epithelial-derived human beta defensin 3 (hBD-3), one of six isolated human beta-defensins containing the characteristic Cys1-Cys-5, Cys2-Cys-4, Cys3-Cys-6 disulfide linkage, is unique among the beta-defensin family [6, 12] . Comprised of a high percentage of the positively charged amino acids arginine and lysine, hBD-3 has the highest net-positive charge (+11) and is salt insensitive [12] , compared to other family members. This high positive charge may contribute to its broad spectrum antimicrobial activity [6] . Unlike other beta-defensins, hBD-3 binds to bacterial products attenuating inflammatory cytokine responses [13] .
HBD-3 expression is induced by various bacterial-derived pathogen associated molecular patterns (PAMPS). Analysis of the hBD-3 promoter reveals STAT1 and AP-1 consensus sequences, implicating interferons (IFN) and growth factors that activate mitogen activated protein kinases (MAPK) as additional regulators of hBD-3 expression [14, 15] .
The production of hBD-3 by keratinocytes, airway epithelial cells and lung-derived epithelial cells [6] , combined with proposed contribution of AMPs in immune tolerance, led to recent reports of hBD-3 mRNA expression within crypt epithelial cells of both the small and large intestine [16] . In addition, the finding that hBD-3 is elevated during chronic inflammation in patients with psoriasis led to studies measuring hBD-3 mRNA expression levels in IBD [16] . HBD-3 mRNA was reported to be increased in inflamed regions of the ulcerative colitis (UC) colon compared to healthy controls [16] , and is unchanged in the CD terminal ileum (TI) and colon. Yet, steroid treatment of patients with CD ileitis and colitis results in reduced hBD-3 mRNA expression in the TI and colon compared to CD patients not receiving steroid treatment [17] . Despite the lack of comparison of hBD-3 mRNA expression to control patients in this study, these results suggest that there is also increased expression of hBD-3 in CD. Thus, the actual expression of hBD-3 in IBD is still uncertain. In addition, the well-established overexpression of specific cytokines that contribute to the severity of each form of IBD suggests that hBD-3 expression should be elevated in CD and depressed in UC. For example, mouse and human studies identify IL-13 as the dominant cytokine within the UC mucosa [18] , yet in vitro studies indicate that IL-13 inhibits the induction of hBD-3 [14] . On the other hand, mouse models of CD as well as human studies establish elevated levels of IFN-γ, IL-17, and IL-22 within the CD mucosa [1, 19] , yet in vitro these cytokines are potent inducers of hBD-3 expression by epithelial cells of various origins, including intestinal epithelial cells [20, 21] . Based on these inconsistencies, in this report we re-examined the expression of both hBD-3 mRNA and peptide in the mucosa from control, UC, and CD donors, using both immunofluorescence and ELISA.
MATERIALS AND METHODS
Patients and clinical materials
Biopsies were obtained after informed consent from patients undergoing scheduled colonoscopies at University Hospitals Case Medical Center (UHCMC, Cleveland, OH).
Protocols were approved by the Institutional Review Board. Two punch biopsies per site were collected from inflamed regions, as appropriate, of the terminal ileum (TI), ascending colon (AC), transverse colon (TC) and descending colon (DC) from CD and UC patients. As a control, two punch biopsies were obtained from the same regions of subjects with no family history of IBD. Biopsies were either fixed in 4% formaldehyde or stored at -80°C until use.
HBD-3 ELISA
Frozen biopsies were placed individually into a siliconized microcentrifuge tube (Fisher Scientific, Pittsburgh, PA) containing a sterile, endotoxin-free metallic bead and Triton X-100 lysis buffer (0.5% Triton X-100, 40 mM Tris-HCl pH 7.4, 120 mM NaCl, 0.3% SDS, deionized H 2 0, 0.15 U/mL aprotonin, 20 mM leupeptin, 0.5 mM Na 3 VO 4 , 2 mM EDTA, 10 mM NaF, 10 mM NaPPi and 2 mM PMSF; (Sigma-Aldrich, St. Louis, MO).
The tissue was homogenized using a bead-beater [Retsch, Newtown, PA] for 3 min at a frequency of 30 Hz/s to ensure all tissue is processed. The resulting homogenate was centrifuged at 12,000 rpm for 60 min to remove any remaining debris, and the supernatant transferred to a clean, sterile microcentrifuge tube. Total protein concentration in the cleared extract was measured using a NanoDrop 1000 (ThermoScientific, Wilmington, DE), and defensin concentration was assayed in an optimized two-site hBD-3 ELISA with paired antibodies, using a rabbit anti-hBD3 capture antibody (Ab) (PeproTech, Rocky Hill, NJ), a biotin-conjugated detection Ab 
Confocal microscopy
After fixation in 4% formaldehyde, biopsies were embedded in paraffin using a clinical automated processor in the UHCMC pathology lab. Blocks were serially sectioned 5-7 µm thick and mounted 3 to a slide. Sections were deparaffinized by rendering the slides through a series of 5 min incubations in xylene, 100% ethanol (ETOH), 95% ETOH and then 70% ETOH (Sigma-Aldrich). Following the removal of paraffin, tissue sections were boiled for 20 min in a citrate buffer solution (DAKO, Carpinteria, CA) in order to optimize antigen retrieval. After cooling, the tissue was washed with 1X PBS and then blocked with 10% donkey serum (Jackson ImmunoResearch Lab, West Grove, PA) overnight in a 4°C cold room. After the overnight blocking, the tissue was washed with 1X PBS to ensure removal of excess donkey serum. On any given slide, one tissue section was incubated for 1 h at room temperature (RT) with a rabbit anti-hBD-3 antibody (Novus Biologicals, Littleton, CO) diluted 1:100 in 5% donkey serum, another tissue section was incubated with rabbit IgG isotype (Zymed, Carlsbad, CA) diluted 1:500 in 5% donkey serum and the remaining tissue section was incubated with 5% 
Gel electrophoresis and immunoblot
To ensure specificity of the primary hBD-3 Ab used for confocal microscopic analysis, 20 ng/well of hBD-3 and HD-5 were fractionated on a 16% Tricine-SDS polyacrylamide gel. Protein was electrotransferred onto a nitrocellulose membrane (Invitrogen, Carlsbad, CA), which was blocked with 5% non-fat dry milk (Nestle, Glendale, CA) in 1X Tris Buffer Solution (TBS) containing 1% Tween-20 (TBST; Fisher Scientific) at room temperature for 60 min and then probed overnight at 4°C under gentle agitation with the primary rabbit anti-hBD-3 Ab used for confocal microscopic studies, diluted 1:1000 into 5% milk in 1X TBST. The membrane was washed with 1X TBST for 30 min with gentle agitation and subsequently probed for 60 min at room temperature with an anti-rabbit HRP-conjugated 2° Ab diluted 1:1000 in 1X TBST. Following incubation with the 2° Ab, the membrane was washed with 1X TBST for 30 min and developed using Supersignal West Pico substrate (ThermoScientific) and chemiluminescence was detected on BioMax MR film (Kodak, Rochester, NY). To ensure specificity for a correctly folded peptide, 20 ng/well and 40 ng/well of hBD-3 and HD-5 were fractionated on a 16% Tricine-SDS polyacrylamide gel and transferred to a nitrocellulose membrane as described above. Prior to incubating the nitrocellulose membrane with the primary rabbit anti-hBD-3 Ab, the Ab was pre-incubated for 60 min at 4°C with a two fold molar excess of synthetic HD-5 peptide (Peptides International) in 5% milk in 1X TBST. The membrane was then probed with the solution containing rabbit anti-hBD-3 primary Ab and synthetic HD-5 peptide overnight at 4°C. The remaining steps were carried out as described previously and chemiluminescence was detected on film.
RNA Extraction
Frozen biopsies were placed into a siliconized microcentrifuge tube (Fisher Scientific) containing an endotoxin and RNase free metallic bead and lysis buffer from the PureLink RNA micro kit (Invitrogen) containing 1% beta-mercaptoethanol (Sigma-Aldrich).
Biopsies were homogenized for 3 min at 30Hz/s using a bead beater (Retsch). The resultant extract was removed from debris by centrifugation for 2 min at 12,000 rpm. 
qRT-PCR
To analyze hBD-3 mRNA expression in intestinal biopsies, 1 µg of RNA was incubated with 25 µg/mL Oligo(dT) [12] [13] [14] [15] [16] [17] [18] and 10 mM (each) dNTP mix at 65°C for 5 min.
Subsequently, 1X first-strand buffer, 0.01 mM DTT and 40 units/µL RNaseOUT (Invitrogen) were added to the reaction mixture and incubated for 2 min at 42°C. The forward hBD-3 primer was ATCTTCTGTTTGCTTTGCTCTTCCTGTTTT and the reverse primer used was AGCACTTGCCGATCTGTTCCTCCTT. For normalization purposes, triplicate identical reactions were set-up on the same 96 well plate with 500 nM forward and reverse eef1α primers (Invitrogen). The forward primer for eef1α was CTTTGGGTCGCTTTGCTGTT and the reverse primer was CCGTTCTTCCACCACTGATT. qPCR was performed on an iCycler (Bio-Rad) using the following reaction conditions: 95°C for 5 min followed by 40 cycles of 95°C for 30 sec and 54°C for 30 sec. Fold change in hBD-3 mRNA was calculated using the ∆∆Ct method, normalizing to eef1α.
Statistical Analysis
Mean hBD-3 concentration was plotted with standard error of the mean (SEM).
Significance of the differences between each patient group was determined by either an ANOVA or two-sided T-test, where appropriate [Excel 2007, Microsoft, Redmond, WA].
P-values less than 0.05 were considered statistically significant.
RESULTS
HBD-3 peptide is expressed in the healthy lower gastrointestinal tract
Multiple inconsistencies exist in the literature regarding the expression profile for hBD-3 mRNA in the healthy and IBD GI tract [16, 22, 23] . In addition, drawing a parallel with the intestinal epithelial cell-derived -defensin HD-5, which is packaged in Paneth cell granules before it is secreted [7, 24] , it is likely that a major discordance between mRNA expression and protein translation or secretion of hBD-3 may exist in the human intestine.
Therefore, to clarify this uncertainty, we chose to analyze hBD-3 protein expression in various sections of the small and large intestine of healthy (control) subjects. Biopsies were obtained from the terminal ileum (TI), ascending colon (AC), transverse colon (TC), and descending colon (DC) of individuals with no family history of IBD undergoing routine, surveillance colonoscopies. After homogenization, a tissue extract was first normalized for total protein content, and then hBD-3 peptide concentrations determined by ELISA [25] . HBD-3 protein is expressed throughout the entire lower gastrointestinal tract, with maximal expression occurring in the ascending colon, although this elevation did not reach statistical significance in our study population (p = 0.129 for all conditions; n=4, Figure 1 ). The production of hBD-3 peptide in the lower gastrointestinal tract reveals the presence of additional antimicrobial defense mechanisms within the gut, and raises the probability that hBD-3 may also contribute to either the establishment or maintenance of mucosal immune tolerance. 
HBD-3 protein localizes to the luminal surface of the intestinal epithelium and within Paneth cell granules in the healthy small intestine
Antimicrobial peptides in the intestine, specifically the α-defensins HD-5 and HD-6 and more recently the Reg family protein RegIIIγ, localize to granules within Paneth cells [10, 24] . Consistent with these observations, hBD-3 mRNA has also been reported within IECs residing near the base of the crypt, as well as those near the surface of the lumen [16] . To contrast the location of hBD-3 mRNA with the sites of peptide accumulation, we identified the expression pattern for hBD-3 protein in the terminal ileum (TI) of the small bowel, a location where high amounts of immunoreactive hBD-3 peptide were found. TI biopsies from healthy donors embedded in paraffin were serially sectioned, mounted onto microscope slides, and labeled with a rabbit anti-human hBD-3 primary were fractionated by gel electrophoresis on a 16% Tricine-SDSpolyacrylamide gel, transferred to a nitrocellulose membrane, and probed with a rabbit anti-hBD-3 Ab, followed by incubation with a goat anti-rabbit-HRP Ab. Signals were developed using Supersignal West-Pico and chemiluminescence was recorded on film. B. HBD-3 and HD-5, at 20 and 40 ng/well, were fractionated as described in panel A, and the resulting membrane was probed with rabbit anti-hBD-3 Ab, after the antibody had been pre-incubated for 60 min at 4°C with a two-fold molar excess of soluble HD-5. The chemiluminescence was recorded on film.
A
HBD-3 peptide and mRNA expression are selectively increased in the Crohn's disease terminal ileum
Crohn's disease is primarily a result of an overt inflammatory response driven by a loss of tolerance to commensal microbiota and their derived antigens [26] . Intestinal epithelial-derived antimicrobial peptides are emerging as important mediators of mucosal homeostasis, limiting interactions of commensal bacteria and antigens with the epithelial and underlying immune cells, respectively, thus acting to prevent inflammatory responses [10, 27] . We therefore propose that changes in AMP expression may alter the homeostatic environment within the intestine, leading to chronic inflammation. Previous reports demonstrate that hBD-3 mRNA expression is decreased in the TI of CD patients, attributed to a frameshift mutation in the NOD2/CARD15 gene encoding a truncated dysfunctional NOD2 receptor [28] , while other reports indicate that a successful antiinflammatory regimen of corticosteroid therapy can reduce hBD-3 mRNA in CD patients [17] . Yet in UC patients, hBD-3 mRNA is reported to be increased in the large intestine [16] . In an attempt to clarify these inconsistencies and to focus more specifically on the biologically relevant hBD-3 peptide itself, hBD-3 peptide was initially measured in intestinal biopsies collected from the terminal ileum (TI), ascending colon (AC), transverse colon (TC), and descending colon (DC) of patients with active CD and UC.
Compared to healthy controls (HC), hBD-3 peptide is selectively increased greater than 2-fold in the TI of CD patients (p = 0.08; n=4 (HC), n=11 (CD), n=5 (UC)), whereas no detectable changes in hBD-3 peptide amounts were observed throughout the large intestine ( Figure 4A) . In contrast to previous publications, no observable increase in hBD-3 peptide was detected throughout the entire large intestine of UC patients ( Figure 4A ). To further investigate and substantiate elevated hBD-3 peptide in the TI of CD patients, hBD-3 peptide was measured in additional HC and CD TI biopsies. In additional clinical samples, elevated hBD-3 peptide is still observed in the CD TI and is increased greater than 3-fold compared to HC subjects ( Figure 4B ; p = 0.059; n=9 (HC) and n=16(CD)). IL-22 expression is reported to be increased within the CD intestine [20] . Thus, we measured IL-22 concentrations by ELISA in the biopsy protein extracts used in Fig. 4A to confirm the presence of active disease. Compared to IL-22 concentrations in the healthy control terminal ileum, we detect an increase in IL-22 in the CD TI ( Figure 4C ; p = 0.08; n=4 (HC), n=11 (CD)). To address discrepancies between the reported decrease in hBD-3 mRNA expression levels in CD ileitis and the increase in hBD-3 peptide described here, we compared hBD-3 mRNA expression levels in HC TI and CD TI biopsies. We found a 2-fold increase in hBD-3 mRNA in the CD TI (n=2 (HC) and 4 (CD)) by qPCR ( Figure 4D ). These results indicate that the inflammatory response in CD, rather than that in UC, induces hBD-3 protein expression, and may suggest discordance between hBD-3 mRNA expression and protein production.
Furthermore, the selective over-expression of hBD-3 in CD possibly implicates additional roles for hBD-3 in regulating the inflammatory response. Transcripts were normalized to eef1α and fold induction was calculated using the ∆∆Ct method.
HBD-3 protein redistributes to the basolateral surface of the villus epithelium and accumulates in the lamina propria of the CD terminal ileum
The intestinal epithelium is polarized; the apical surface samples the luminal contents and Actively inflamed Crohn's disease tissue, in which hBD-3 is redistributed along the basolateral surface of the epithelium, with elevated expression in the adjoining lamina propria. D. Tissue from a CD patient, in whom inflammation of the TI was inactive. While staining for hBD-3 in the lamina propria is reduced, possibly due to the diminished inflammatory cell infiltration, hBD-3 accumulates along the basolateral surface of the epithelium in inactive disease. Arrows indicate the apical or basolateral location of hBD-3 signal.
Discussion
In this study, we demonstrated that the peptide expression level and anatomical distribution of hBD-3 are distinct in the healthy and chronically inflamed IBD intestine.
HBD-3 peptide is expressed in the healthy lower gastrointestinal tract, localized to Paneth cell granules and along the apical surface of the epithelium in the terminal ileum. In contrast to previous studies of hBD-3 mRNA expression [16] , we show elevated hBD-3 peptide and mRNA in the terminal ileum of Crohn's ileitis patients. Unlike in the healthy terminal ileum, hBD-3 peptide localization in the CD terminal ileum redistributes to the basolateral surface of the epithelium and also accumulates in the lamina propria, only in active disease. The apical orientation of hBD-3, its presence in Paneth cell granules, and its broad spectrum antimicrobial activity suggest that in the healthy mucosa hBD-3 is secreted into the lumen and functions to keep the crypt sterile, thus contributing an important role in maintaining mucosal tolerance within the intestine.
The intestinal mucosa is unique compared to other mucosal sites, such that immunocompetent cells do not mount an overt inflammatory response in the presence of continual stimulation from the commensal microbiota and derived antigens that are separated by an epithelial barrier only a single cell layer thick [2] . This phenomenon is defined as immune tolerance and is critical for proper function of the gastrointestinal tract [2] . It is well established that tolerance is maintained by a delicate balance between various innate and adaptive immune cells [1] . To further understand mechanisms important for establishing and sustaining tolerance, investigators studied inflammatory bowel disease, which is widely believed to represent a pathological loss of tolerance.
Genetic analyses identified multiple genes that increase the susceptibility of IBD onset [2] , among which were those important for epithelial cell immunological function, implicating the epithelium as an important mediator of mucosal tolerance [2] . The epithelium, in addition to being a physical barrier, secretes antimicrobial peptides produced by Paneth cells that act as a chemical barrier to provide a sterile crypt environment preventing the attachment and invasion of commensal bacteria, thereby limiting the interaction of commensal antigens with intestinal immune and epithelial cells and preventing an overt, uncontrolled inflammatory response [10, 26, 27] . This is best evidenced in a mouse model lacking Paneth cells, in which translocation and invasion of commensal bacteria into the mesenteric lymph node is increased [10] . In the human intestine, this concept is confirmed by the storage of the alpha defensins, HD-5 and HD-6, within Paneth cell granules [24] . In addition to alpha defensins, another class of AMPs, beta defensins, is also primarily produced by epithelial cells [6] . Of the six isolated human beta defensins, human beta defensin 3 (hBD-3), possesses the most potent broad spectrum antimicrobial activity, able to kill both gram negative and positive bacteria and multiple viruses and fungi [12] . Thus, it may serve to protect and maintain epithelial homeostasis upon microbial challenge or invasion.
In this study, using intestinal biopsies collected from the terminal ileum, ascending colon, transverse colon and descending colon of healthy control patients, hBD-3 peptide was detected within the terminal ileum and throughout the entire length of the colon.
Maximal hBD-3 protein expression occurs within the ascending colon, possibly due to the exponential increase in bacterial load from the terminal ileum to the ascending colon [29] . HBD-3 may prevent the invasion of commensal bacteria into the terminal ileum, which may not be designed to handle an elevated bacterial load, as increased pattern recognition receptor (PRR) expression, such as TLR4, is reported to be higher in the TI compared to the colon [30] . Confocal microscopy reveals hBD-3 protein stored within Paneth cell granules. Previously identified AMPs with similar structure are also stored in Paneth cell granules [24] . To rule out hBD-3 antibody cross-reactivity with such AMPs, a competitive immunoblot demonstrates that the hBD-3 antibody used for confocal microscopy does not recognize denatured and native epitopes of Paneth cell specific HD- In contrast to the hypothesis that Crohn's ileitis is associated with decreased AMP expression, we report a three-fold increase in hBD-3 peptide within the terminal ileum of these patients. HBD-3 protein levels in all colonic regions of Crohn's ileitis patients were similar to those detected in the healthy colon. Thus, it seems that hBD-3 protein is selectively increased in the TI of patients with ileitis; however additional patient samples are required to reach statistical significance. To confirm the presence of active disease in our patient samples, we measured IL-22 concentrations in biopsy extracts. In agreement with previously published studies [20] , we report elevated levels of IL-22 in ileitis biopsies compared to healthy control. Due to the inconsistency between the increase hBD-3 peptide in Crohn's ileitis presented in this report and the decrease in hBD-3 mRNA expression described in current literature [16] , we measured hBD-3 mRNA in ileal biopsies obtained from healthy controls and Crohn's ileitis patients. Thus far, we observed approximately a 2-fold increase in hBD-3 mRNA in the terminal ileum of CD patients. With larger numbers of subjects, a significant increase in hBD-3 mRNA in CD patients is likely to be recorded. If no significant hBD-3 mRNA increase is observed following the addition of more subjects, it may be possible that regulation of hBD-3 mRNA expression is cyclic, indicating strict post-transcriptional, regulatory mechanisms control hBD-3 production. It also remains to be determined if patients enrolled in the current study carry the Leu1007fsinsC mutation. Therefore, conclusions cannot be drawn regarding the effect of NOD2 mutations on hBD-3 protein expression. Future experiments are required to determine if a correlation exists between NOD2 polymorphisms and hBD-3 expression levels. Discrepancies between our data of elevated hBD-3 protein and the current hypothesis that a decrease in AMPs contributes to the onset of CD can possibly be explained by 1) lack of NOD2-dependent regulation of hBD-3 expression or 2) severity of disease in different patient populations. Severity of disease has been reported to correlate with decreased AMP expression due to epithelial deterioration resulting in fewer cells capable of producing AMPs [31] . Previous studies implicating a correlation between NOD2 polymorphisms with decreased AMP expression failed to evaluate the histological integrity of the intestinal sections used, thus lessening a direct contribution of NOD2 mutations to decreased AMP expression in active disease [27, 28] .
In addition to an increase in hBD-3 protein levels, we also describe a change in hBD-3 localization in the terminal ileum of Crohn's ileitis patients. In active CD, hBD-3 is redistributed to the basolateral surface of the epithelium and accumulates within the lamina propria. HBD-3 remains localized to the basolateral surface in the terminal ileum of inactive ileitis, however, the accumulation of hBD-3 within the lamina propria is lost.
These findings suggest that the intestinal epithelium senses a change in the distribution of "danger signals." We propose that since Crohn's disease patients, with active and inactive disease, who have defective epithelial barrier function allowing for possible translocation of commensal bacteria [32, 33] , respond by actively redirecting defense proteins such as hBD-3 to restore protection. HBD-3 remaining localized to the basolateral surface in an inactive region of CD may suggest epithelial "memory," allowing for a quick response if disease activity were to reinitiate at the same location, or a permanent change in epithelial cell physiology.
Intestinal epithelial cells are polarized with an apical and basolateral membrane. The phenotypic and biologic function of each membrane is distinct due to differential protein distribution [34] . Key regulators of intestinal epithelial cell polarization are Rab proteins, which are small intracellular GTPases that regulate intracellular protein trafficking [35] .
Distinct Rab GTPases associate with proteins as they exit the trans-Golgi network (TGN) and shuttle proteins to either the apical or basolateral membrane. Up to 70 different Rab proteins have been identified [35] . Depending on which Rab protein associates with a protein exiting the TGN, the protein is either shuttled to the apical, basolateral or both membranes [35] . For example, Rab18 transports proteins to both the basolateral and apical membrane, whereas Rab3 and Rab14 shuttle proteins solely to the apical membrane [34, 36, 37] . Currently, it remains unknown if inflammatory diseases alter the repertoire of Rab proteins within epithelial cells, thus changing the spatial distribution of proteins. It is reported, however, IL-6 and IL-12 regulate Rab5 and Rab7 expression, respectively [38] . IL-6 induction of Rab5 redirects proteins to early endocytic compartments, whereas IL-12 induction of Rab7 redirects proteins to lysosomes [38] .
Thus, cytokines implicated in inflammatory diseases may regulate spatial distribution of immune effector proteins in the epithelium. Therefore, we propose that CD is not only 
